Comment: Using enzalutamide will allow patients to avoid chemotherapy and steroids improving quality of life

Bookmark and Share
Published: 2 Jun 2019
Views: 400
Dr Neeraj Agarwal - Huntsman Cancer Institute, Salt Lake City, USA

Dr Neeraj Agarwal comments on data, during a press conference at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, from the ENZAMET trial.

This was a phase III internationally randomised trial in which patients with mHSPC who received testosterone suppression were also given enzalutamide.

Watch Dr Sweeney's press conference here, and interview here.